Business Wire

MD-IPROOV

7.6.2022 09:02:10 CEST | Business Wire | Press release

Share
What Does the Future of Travel Look Like? A Majority of Consumers Favor a Journey Straight from the Couch to the Gate

As the summer travel season kicks off, consumers are ready to take to the skies to get away to relaxing vacations. The only problem? Getting there.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005376/en/

A new consumer survey released today by iProov , the world leader in biometric face authentication technology, found that travelers do not find the airport check-in process a relaxing first step to a destination. In fact, a majority of those surveyed would prefer to streamline the process to go straight from their couch at home to the gate in as few steps as possible.

Eighty-five percent (85%) of the 16,000 respondents in eight countries would use or would consider using a ticket/ID check from home. Further, 70% of respondents said the first step of the journey–waiting in long check-in lines–is the most annoying part of traveling.

So, how can airports and airlines reduce the bottlenecks during journeys using check-from-home services to make the travel experience more convenient for consumers? Secure remote verification technology enables travelers to complete their ticket and ID checks from the comfort of their homes, so they don't need to do it at the airport. The key to this process is facial biometric verification and authentication.

“Secure verification technology enables travelers to complete their ticket and ID checks from the comfort of their homes, so they don't need to do it at the airport,” said Andrew Bud, Founder and CEO of iProov. “Facial biometric verification and authentication are key to this process. Face verification has already proved to be a secure and accessible solution for many applications and processes–for example, nearly a third of consumers are already using face verification to access their mobile banking apps. We’ve shown that online face verification can be applied to improve the consumer travel experience, making life easier for travelers and operators around the world.”

iProov’s Genuine Presence Assurance® offers a brief, passive face scan that confirms a remote traveler is the right person, matching the identity to a trusted identity document and ticket. The technology also verifies that the user is a real person and not a presentation attack using a photo or mask, and that they are authenticating in real time. At the airport, a traveler’s face is their ticket as they choose to pass through a biometric corridor and authenticate their identity.

This technology solution is not unique to the airline industry and can be applied to eliminate check-in bottlenecks for other forms of travel, including trains, cruise ships, car hires and more. In fact, earlier this year, iProov partnered with Eurostar for the successful trial of a remote fast-track service, SmartCheck, showing that the future of travel is not so distant.

To learn more about iProov and the future of travel, please visit the Biometric Travel & Check-In section of our website.

Methodology

This report is based on research carried out by an independent agency on behalf of iProov in April–May 2022. Eight countries were included in the research (the U.S., Canada, Mexico, Germany, Italy, Spain, the UK and Australia), with 2000 consumers surveyed in each country. The 16,000 respondents were not chosen for any preferences on travel–many had never flown before.

About iProov

Launched in 2013, iProov is the world leader in online facial biometric authentication, working with governments, banks and other enterprises to securely verify customer identity. Used for effortless onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), the Australian Taxation Office, GovTech Singapore, Rabobank, ING, and others. iProov’s technologies include Liveness Assurance™ and Genuine Presence Assurance® , which ensures that an online customer is the right person, a real person, and is authenticating right now. This protects against spoof attacks from photos, videos, masks and digital injection attacks and the emerging threat of deepfakes. iProov was recognized as a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection. For more information, please see www.iproov.com or follow us on LinkedIn or Twitter .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye